- The GP2 Phase III clinical trial design was presented in a poster during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, providing an open label arm and potentially valuable data that can be
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who